← board
AAPG
distress 1/10 · well-funded / low risk$19.23+1%today-60% from 52w high
Revenue
$574M
Liquidity
$2501M
Runway
2.1 yrs
Shares 1y
0%
Price & events
-26.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.7%
1D
-4.7%
1W
+12.3%
1M
-23.5%
3M
-26.6%
6M
-51.2%
1Y
—
2Y
—
5Y
+10.7%
All
Overview
- Market Cap
- $7.18B
- Enterprise Value
- $5.46B
- Volume
- 11.60K
- 52 Week Range
- $16.77 – $47.90
- Total Shares
- 373.32M
- Float Shares
- 71.04M
- Short %
- 0.21%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 0.06%
- RVOL
- 0.77x
- Beta
- 0.66
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $48 (+147% upside) · 9 analysts
- 2026-06-15BTIGBuy
- 2026-06-10B. Riley SecuritiesBuy
- 2026-04-13BTIGBuy
- 2026-03-26BTIGBuy
- 2025-12-04OppenheimerOutperform
- 2025-11-24Truist SecuritiesBuy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.